Question explored with the scientific record
Do T3 or T4 thyroid hormone supplements actually help treatment-resistant depression, and do the trials agree?
The trials do not agree, and the disagreement is the finding.
The evidence for thyroid hormone in treatment-resistant depression is thin, old, and split by design. A 1993 placebo-controlled trial in unipolar refractory depression found T3 (liothyronine) beat placebo as an add-on to tricyclic antidepressants, and matched lithium, with no significant difference between the two active drugs [3]. That is the strongest design here, and it is a single small trial from three decades ago. A 1998 review of the thyroid axis and depression reported that roughly 3 of 4 double-blind trials suggested T3 benefit in tricyclic nonresponders, total N around 62, with one trial showing no advantage [5]. That is a handful of tiny studies, not a settled result.
The newer controlled data point the other way, and toward T4. A 2018 double-blind placebo-controlled trial in rapid cycling bipolar disorder found levothyroxine (T4) significantly cut time in depressed and mixed states, while T3 did not beat placebo [2]. Note the population: bipolar, not unipolar. The uncontrolled records are weaker still. A 2009 retrospective chart review of high-dose T3 in treatment-resistant bipolar II reported 84% improvement and 33% remission, but it was open-label, uncontrolled, and retrospective, and it recorded bone loss and one atrial fibrillation case [1]. A 2022 case report of high-dose T4 plus TMS, lurasidone, and lithium in one patient cannot separate the drug from the rest [4].
| Study | Design | Population | Result |
|---|---|---|---|
| 1993 trial [3] | Placebo-controlled | Unipolar refractory | T3 beat placebo |
| 1998 review [5] | Review of blinded trials | TCA nonresponders | 3 of 4 favored T3 |
| 2018 trial [2] | Double-blind, placebo | Rapid cycling bipolar | T4 helped, T3 did not |
| 2009 review [1] | Retrospective, uncontrolled | Bipolar II/NOS | 84% improved, no control |
What this retrieval cannot see: it surfaced no large modern randomized trial of T3 or T4 in unipolar treatment-resistant depression, and no long-term safety data on bone or heart rhythm at augmentation doses. The mechanism is plausible, T3 raising brain serotonin and altering receptor gene expression [6], but plausible is not proven. The harms are real: tremor, bone loss, and atrial fibrillation appeared even in the uncontrolled record [1].
My call: T3 has modest, old, mixed support as an add-on in unipolar refractory depression, T4 has one controlled win in bipolar rapid cycling, and neither is established for treatment-resistant depression broadly. Confidence: low.
Sources used 6
-
The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS
A retrospective chart review evaluating high-dose triiodothyronine (T3) augmentation for treatment-resistant bipolar II disorder and bipolar disorder NOS, finding high response/remission rates with tolerable safety despite an uncontrolled design.
DOI: 10.1016/j.jad.2008.12.010 -
Adjunctive thyroid hormone treatment in rapid cycling bipolar disorder: A double‐blind placebo‐controlled trial of levothyroxine (L‐T 4 ) and triiodothyronine (T 3 )
This study presents the first double-blind, placebo-controlled trial comparing the effects of levothyroxine (L-T4) and triiodothyronine (T3) as adjunctive treatments in patients with rapid cycling bipolar disorder, finding that L-T4 significantly reduces time spent in depressed …
DOI: 10.1111/bdi.12657 -
A Placebo-Controlled Comparison of Lithium and Triiodothyronine Augmentation of Tricyclic Antidepressants in Unipolar Refractory Depression
This study compares the efficacy of lithium carbonate and liothyronine sodium in augmenting the therapeutic response of tricyclic antidepressants in patients with unipolar refractory depression, finding both to be significantly more effective than placebo but not significantly d…
DOI: 10.1001/archpsyc.1993.01820170065008 -
High dose Levothyroxine in combination with transcranial magnetic stimulation for the treatment of severe resistant subthreshold rapid cycling bipolar disorder; A case report
In a treatment-resistant rapid-cycling bipolar I patient with subthreshold symptoms, combined high-dose levothyroxine, rTMS, lurasidone, and lithium was followed by full remission by 7 months and maintenance for 2.5 years.
DOI: 10.17352/apt.000044 -
The Thyroid Axis and Depression
A comprehensive review linking depression to thyroid-axis abnormalities and proposing thyroid hormone augmentation (especially T3) as a potential adjuvant therapy for resistant depression, while highlighting the need for robust controlled trials.
DOI: 10.1089/thy.1998.8.951 -
Basic Mechanisms of Augmentation of Antidepressant Effects with Thyroid Hormone
This study investigates the mechanisms by which the thyroid hormone triiodothyronine (T3) enhances the effects of antidepressants, particularly focusing on its interaction with serotonergic neurotransmission and gene transcription.
DOI: 10.2174/138945006775515482